本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

Passage Bio, Inc.

0.3300
+0.00100.30%
盤後0.33000.00000.00%18:19 EDT
成交量:15.75萬
成交額:5.19萬
市值:2,050.89萬
市盈率:-0.31
高:0.3600
開:0.3300
低:0.3134
收:0.3290
資料載入中...

公司資料

公司名字:
Passage Bio, Inc.
交易所:
NASDAQ
成立時間:
2017
員工人數:
60
公司地址:
One Commerce Square,2005 Market Street,39th Floor,Philadelphia,Pennsylvania,United States
郵編:
19103
傳真:
- -
簡介:
Passage Bio, Inc.是一家位於特拉華州的公司,成立於2017年7月26日,是一家專註於開發罕見的單基因中樞神經系統疾病的轉化療法的基因藥物公司。其願景是成為領先的基因藥物公司,並积極改變因為遭受這些疾病而受到生命威脅的患者生活。

董事

名稱
職位
Bruce Goldsmith
Chief Executive Officer, President and Director
Stephen Squinto
Acting Head of Research and Development and Director
Athena Countouriotis
Director
Liam Ratcliffe
Director
Patrick Heron
Director
Sandip Kapadia
Director
Saqib Islam
Director
Tadataka Yamada
Director
Tom Woiwode
Director

股東

名稱
職位
Bruce Goldsmith
Chief Executive Officer, President and Director
Jill M. Quigley
Chief Operating Officer
Richard S. Morris
Chief Financial Officer
Alex Fotopoulos
Chief Technical Officer
Edgar B. Cale
General Counsel and Corporate Secretary
Gary Romano
Chief Medical Officer
Stephen Squinto
Acting Head of Research and Development and Director